Literature DB >> 18950559

LDL reduction: how low should we go and is it safe?

Jennifer G Robinson1.   

Abstract

High-dose statin therapy or combination statin treatment is necessary for most patients to achieve aggressive low-density lipoprotein cholesterol goals. Adding ezetimibe or bile acid sequestrants appears unlikely to increase the risk of myopathy. Although the combination of niacin or fenofibrate with moderate-dose statins appears to be reasonably safe, the safety of combination with high-dose statins has yet to be determined. To enhance patient outcomes, attention must be paid to characteristics that predict muscle and hepatic statin toxicity when considering using high-dose statin or combination statin therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950559     DOI: 10.1007/s11886-008-0076-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  39 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Statin safety: an appraisal from the adverse event reporting system.

Authors:  Michael H Davidson; John A Clark; Lucas M Glass; Anju Kanumalla
Journal:  Am J Cardiol       Date:  2006-02-03       Impact factor: 2.778

3.  Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study.

Authors:  Heather M Johnson; Pamela S Douglas; Sathanur R Srinivasan; M Gene Bond; Rong Tang; Shengxu Li; Wei Chen; Gerald S Berenson; James H Stein
Journal:  Stroke       Date:  2007-02-01       Impact factor: 7.914

4.  Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.

Authors:  Robert H Knopp; Christine Tsunehara; Barbara M Retzlaff; Brian Fish; Hien Nguyen; Susan Anderson; Thuy Nguyen
Journal:  Metabolism       Date:  2006-12       Impact factor: 8.694

5.  Identifying patients for aggressive cholesterol lowering: the risk curve concept.

Authors:  Jennifer G Robinson; Neil J Stone
Journal:  Am J Cardiol       Date:  2006-10-02       Impact factor: 2.778

6.  Striated muscle safety of ezetimibe/simvastatin (Vytorin).

Authors:  Michael H Davidson; Darbie Maccubbin; Michael Stepanavage; John Strony; Thomas Musliner
Journal:  Am J Cardiol       Date:  2005-11-21       Impact factor: 2.778

7.  Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

Authors:  Christie M Ballantyne; Michael H Davidson; James McKenney; Laurence H Keller; Daiva R Bajorunas; Richard H Karas
Journal:  Am J Cardiol       Date:  2008-05-15       Impact factor: 2.778

Review 8.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.

Authors:  M Law; N Wald; J Morris
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

9.  Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

Authors:  Paul N Durrington; Jaakko Tuomilehto; Andreas Hamann; David Kallend; Karen Smith
Journal:  Diabetes Res Clin Pract       Date:  2004-05       Impact factor: 5.602

10.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

Authors:  Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  1 in total

1.  Fenofibrate Interferes with the Diapedesis of Lung Adenocarcinoma Cells through the Interference with Cx43/EGF-Dependent Intercellular Signaling.

Authors:  Katarzyna Piwowarczyk; Edyta Kwiecień; Justyna Sośniak; Eliza Zimoląg; Emiliana Guzik; Jolanta Sroka; Zbigniew Madeja; Jarosław Czyż
Journal:  Cancers (Basel)       Date:  2018-09-28       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.